When Trial Participation Counts: Publication, Representativeness, and the Completeness of Oncology Evidence

The Legacy of Clinical Trial Results

The Clinical Trial Results (CTR) section of The Oncologist was launched in 2012 to address a persistent gap in oncology research: the underpublication of trial results. Trials that are negative, fail to meet accrual targets, or close early are often left unpublished, leaving patient participation invisible and scientific knowledge incomplete.1 Susan Bates and Tito Fojo helped establish CTR as a templated, peer-reviewed venue that ensures these studies still count.2 Rather than requiring traditional manuscripts, CTR uses a concise extended abstract format to disseminate key findings rapidly, ensuring that trial data, even those that might not meet conventional standards of “success”, contribute to the scientific record.1,2

Publication Bias and the Cost of Silence

The rationale for CTR was not theoretical. Oncology trials frequently go unpublished, particularly those with negative or inconclusive findings. One analysis of trials presented at ASCO found that 39% remained unpublished, with randomized trials showing a 25% nonpublication rate.3 Trials with nonsignificant results had lower publication rates than those with significant findings (68% vs 81% at 5 years), contributing to bias that distorts meta-analyses, guidelines, and treatment decisions.4, 5, 6 This selective reporting creates a literature skewed toward positive findings, potentially leading clinicians to overestimate treatment efficacy or pursue therapies with limited evidence. CTR was designed to counter this, providing a mechanism to ensure that patient contribution is preserved and visible, even when results do not change practice.1

A Parallel Gap: Representativeness of Trial Populations

CTR addressed one form of evidence incompleteness: the loss of trial results to nonpublication. A related challenge is the incompleteness of trial populations themselves. Evidence that is published may still lack relevance if enrolled patients do not reflect the diversity and complexity of real-world care. In gynecologic cancers, including cervical cancer, this gap is particularly striking. In gynecologic cancer research, underrepresentation remains a concern: a large cohort study of women with endometrial, ovarian, or cervical cancer found that Asian, Black, and Hispanic women had lower odds of clinical trial enrollment, while white women were overrepresented across cancer types.7 Trials often exclude older adults, patients with comorbidities, and individuals treated outside academic centers, which are the groups that represent the majority of clinical practice.4

The Global Burden and the Stakes of Representativeness

The implications are especially urgent in high-burden settings. In Africa, 1.1 million new cancer cases and 711,429 cancer deaths were reported in 2020, with projections reaching 2.1 million new cases and 1.4 million deaths by 2040.8, 9 Cervical cancer, driven by HPV, remains a leading cause of cancer mortality, particularly in regions where screening and treatment access are limited.10, 11 Yet the trial evidence guiding care is often generated in settings that do not reflect these realities, raising questions about generalizability in resource-constrained environments.7

Making Evidence Count: A Unified Principle

CTR’s legacy is that trial participation should count regardless of outcome. The field now faces a parallel responsibility: ensuring that participation also counts by generating evidence relevant to real-world patients. Oncology cannot afford to lose knowledge either to nonpublication or to narrow generalizability. Both problems undermine the scientific record and the patients who depend on it.4, 5, 6

Toward Complete Evidence

The path forward requires attention to both ends of the evidence chain: publishing all useful trial results and designing studies that reflect clinical diversity. CTR showed that oncology can value imperfect data. The next step is to extend that principle to imperfect representation, ensuring that trial evidence is not only visible, but also applicable.1, 6

References

  1. Fojo AT, Bates SE, Chabner BA. Clinical trial results: Sharing results, speeding discoveries. Oncologist. 2013;18(7):779. doi: 10.1634/theoncologist.2013-0247. PMID: 23882019; PMCID: PMC3720628.
  2. Fojo AT, Bates SE. Clinical trial results: a clinical trial bazaar! Oncologist. 2014 Apr;19(4):313-4. doi: 10.1634/theoncologist.2014-0091. Epub 2014 Mar 25. PMID: 24668329; PMCID: PMC3983835.
  3. Sacher A, Bates SE. Early phase trials: the perils of nonpublication. Oncologist. 2025 Apr 4;30(4):oyaf041. doi: 10.1093/oncolo/oyaf041. PMID: 40271638; PMCID: PMC12019221.
  4. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003 Jul 23;290(4):495-501. doi: 10.1001/jama.290.4.495. PMID: 12876092.
  5. Laviolle B, Locher C, Allain JS, Le Cornu Q, Charpentier P, Lefebvre M, Le Pape C, Leven C, Palpacuer C, Pontoizeau C, Bellissant E, Naudet F. Trends of Publication of Negative Trials Over Time. Clin Pharmacol Ther. 2025 Mar;117(3):818-825. doi: 10.1002/cpt.3535. Epub 2025 Jan 5. PMID: 39757525; PMCID: PMC11835424.
  6. Leal AI, et al. Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings. J Clin Oncol 28, 6116-6116(2010). doi:10.1200/jco.2010.28.15_suppl.6116
  7. Kao J, Ross JS, Miller JE. Transparency of Results Reporting in Cancer Clinical Trials. JAMA Netw Open. 2023 Aug 1;6(8):e2328117. doi: 10.1001/jamanetworkopen.2023.28117. PMID: 37556143; PMCID: PMC10413165.
  8. Omotoso O, Teibo JO, Atiba FA, Oladimeji T, Paimo OK, Ataya FS, Batiha GE, Alexiou A. Addressing cancer care inequities in sub-Saharan Africa: current challenges and proposed solutions. Int J Equity Health. 2023 Sep 11;22(1):189. doi: 10.1186/s12939-023-01962-y. PMID: 37697315; PMCID: PMC10496173.
  9. Rose I Anorlu, Lemchukwu C Amaeshi, Kehinde S Okunade, Adeyemi A Okunowo, Ephriam O Ohazurike, Adaiah P Soibi Harry, Okechukwu N Duru, Ann Murphy, Cancer: a looming public health crisis in Africa—a call to accelerate equitable access to medicines, The Oncologist, Volume 31, Issue 5, May 2026, oyag089, https://doi.org/10.1093/oncolo/oyag089
  10. WHO AFRO Investment Case Series: Cervical Cancer and HPV Vaccination. 2024. https://www.afro.who.int/publications/who-afro-investment-case-series-accelerating-cervical-cancer-elimination-africa.
  11. Stefan DC, Dangou JM, Barango P, Mahamadou ID, Kapambwe S. The World Health Organization targets for cervical cancer control by 2030: a baseline assessment in six African countries-part I. Ecancermedicalscience. 2022 Oct 7;16:1453. doi: 10.3332/ecancer.2022.1453. PMID: 36405945; PMCID: PMC9666282.